Stockreport

Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones

Vigil Neuroscience, Inc.  (VIGL) 
PDF – On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer’s disease in 1Q 2025 – – Final analysis from IGNITE Phase 2 clin [Read more]